

Christoph Correll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/344910/publications.pdf>

Version: 2024-02-01

589
papers

46,234
citations

1301

109
h-index

2953

189
g-index

610
all docs

610
docs citations

610
times ranked

26816
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 4064-4082.	4.5	9
2	Characteristics prior to and at time of diagnosis in pediatric bipolar disorder. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 282-292.	1.3	0
3	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	1.2	11
4	Motor activity patterns can distinguish between interepisode bipolar disorder patients and healthy controls. <i>CNS Spectrums</i> , 2022, 27, 82-92.	1.2	9
5	Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 781-793.	4.7	5
6	Emotional abuse interacts with borderline personality in adolescent inpatients with binge-purging eating disorders. <i>Eating and Weight Disorders</i> , 2022, 27, 131-138.	2.5	5
7	Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. <i>Molecular Psychiatry</i> , 2022, 27, 281-295.	7.9	967
8	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
9	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 166-175.	4.3	26
10	Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. <i>Psychiatric Services</i> , 2022, 73, 249-258.	2.0	13
11	Editorial Perspective: Challenges of research focusing on child and adolescent mental health during the COVID-19 era: what studies are needed?. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 122-125.	5.2	12
12	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306.	4.3	21
13	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , 2022, 54, 90-99.	0.7	5
14	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
15	Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms. <i>European Psychiatry</i> , 2022, 65, 1-27.	0.2	10
16	Long-term efficacy and safety of once-monthly Risperidone ISMÂ® in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , 2022, 239, 83-91.	2.0	5
17	A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. <i>Journal of Medical Virology</i> , 2022, 94, 1935-1949.	5.0	134
18	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. <i>BMC Psychiatry</i> , 2022, 22, 32.	2.6	11

#	ARTICLE	IF	CITATIONS
19	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. <i>British Journal of Psychiatry</i> , 2022, 221, 591-602.	2.8	29
20	Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, , .	0.5	7
21	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. <i>Schizophrenia Research</i> , 2022, 240, 205-213.	2.0	3
22	Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice. <i>Pharmacopsychiatry</i> , 2022, 55, 255-265.	3.3	14
23	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	2.2	3
24	Lifetime prevalence and clinical correlates of nonsuicidal self-injury in youth inpatients with eating disorders: a retrospective chart review. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2022, 16, 17.	2.5	7
25	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. <i>NPJ Schizophrenia</i> , 2022, 8, 5.	3.6	48
26	The Impact of Inpatient Multimodal Treatment or Family-Based Treatment on Six-Month Weight Outcomes in Youth with Anorexia Nervosa: A Naturalistic, Cross-Continental Comparison. <i>Nutrients</i> , 2022, 14, 1396.	4.1	2
27	Reliability and Validity of the Bipolar Prodrome Symptom Interview and Scale-Full Prospective in Its Turkish Translation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 178-186.	1.3	5
28	Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. <i>Lancet Psychiatry</i> , the, 2022, 9, 271-279.	7.4	25
29	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540.	3.2	6
30	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , the, 2022, 9, 291-306.	7.4	6
31	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	6.1	67
32	Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. <i>Comprehensive Psychiatry</i> , 2022, 115, 152301.	3.1	13
33	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
34	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 774-784.	4.3	9
35	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.2	4
36	Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2022, 19, e1003960.	8.4	43

#	ARTICLE	IF	CITATIONS
37	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 795866.	2.6	8
38	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. <i>Molecular Psychiatry</i> , 2022, 27, 3510-3519.	7.9	29
39	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	10.4	156
40	Outcomes of a Standardized, High-Caloric, Inpatient Re-Alimentation Treatment Protocol in 120 Severely Malnourished Adolescents with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2022, 11, 2585.	2.4	6
41	Oral and long-acting antipsychotics for relapse prevention in schizophrenia spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	10.4	44
42	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. <i>European Neuropsychopharmacology</i> , 2022, 59, 45-55.	0.7	7
43	Randomized controlled trial of cognitive remediation therapy in adolescent inpatients with anorexia nervosa: Neuropsychological outcomes. <i>European Eating Disorders Review</i> , 2022, 30, 772-786.	4.1	5
44	Drug-drug interactions involving antipsychotics and antihypertensives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 285-298.	3.3	4
45	Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. <i>Schizophrenia Bulletin</i> , 2022, 48, 1021-1031.	4.3	7
46	Age dependency of body mass index distribution in childhood and adolescent inpatients with anorexia nervosa with a focus on DSM-5 and ICD-11 weight criteria and severity specifiers. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1081-1094.	4.7	12
47	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021, 51, 1570-1580.	4.5	17
48	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	1.2	13
49	Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. <i>Bipolar Disorders</i> , 2021, 23, 117-129.	1.9	53
50	Practice-Based Evidence and Clinical Guidance to Support Accelerated Re-Nutrition of Patients With Anorexia Nervosa. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 555-561.	0.5	19
51	Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 657-673.	5.2	95
52	What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab013.	1.7	8
53	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 565-573.	6.1	14
54	Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 864-874.	4.3	21

#	ARTICLE	IF	CITATIONS
55	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 948-958.	4.3	26
56	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 454-464.	1.3	5
57	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 198-205.	2.0	16
58	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). <i>Schizophrenia Research</i> , 2021, 228, 438-446.	2.0	2
59	Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared With Management as Usual for Youth With Common Mental Health Problems. <i>JAMA Psychiatry</i> , 2021, 78, 250.	11.0	28
60	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. <i>Journal of Psychopharmacology</i> , 2021, 35, 1081-1090.	4.0	9
61	Cardiometabolic Safety of Lumateperone (ITIâˆ’007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 152-152.	1.2	1
62	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 189-202.	1.7	32
63	How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 323-326.	1.4	3
64	Safety and Effectiveness of SEPâˆ’363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study. <i>CNS Spectrums</i> , 2021, 26, 148-149.	1.2	12
65	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. <i>CNS Spectrums</i> , 2021, , 1-13.	1.2	0
66	Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. <i>CNS Spectrums</i> , 2021, 26, 147-147.	1.2	2
67	Occurrence and accuracy of a register-based diagnosis of pediatric bipolar disorder: A nationwide cohort study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1101-1108.	2.3	1
68	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and preâ€“post studies. <i>Lancet Psychiatry</i> , 2021, 8, 387-404.	7.4	160
69	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , 2021, 178, 424-436.	7.2	54
70	Association of Low-Dose Quetiapine and Diabetes. <i>JAMA Network Open</i> , 2021, 4, e213209.	5.9	14
71	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. <i>Schizophrenia Bulletin</i> , 2021, 47, 1621-1630.	4.3	24
72	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.5	6

#	ARTICLE	IF	CITATIONS
73	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 510.	11.0	63
74	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	10.4	183
75	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. <i>World Psychiatry</i> , 2021, 20, 244-275.	10.4	76
76	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Psychiatry</i> , 2021, 8, 471-486.	7.4	36
77	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , 2021, 11, 360.	4.8	8
78	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100909.	7.1	25
79	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1611-1620.	4.3	33
80	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 364-375.	1.3	4
81	Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply. <i>Lancet Psychiatry</i> , 2021, 8, 567.	7.4	2
82	Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. <i>International Journal of General Medicine</i> , 2021, Volume 14, 4081-4094.	1.8	4
83	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 23.	2.2	3
84	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. <i>Schizophrenia Research</i> , 2021, .	2.0	4
85	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. <i>Psychiatry Research</i> , 2021, 301, 113963.	3.3	1
86	Validity of the Aktibipo Self-rating Questionnaire for the Digital Self-assessment of Mood and Relapse Detection in Patients With Bipolar Disorder: Instrument Validation Study. <i>JMIR Mental Health</i> , 2021, 8, e26348.	3.3	0
87	Long-acting antipsychotics: is what we know really so? – Authors' reply. <i>Lancet Psychiatry</i> , 2021, 8, 651-652.	7.4	0
88	Measurement-based Diagnosis and Treatment for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	2
89	A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 329-341.	4.5	27
90	Huntington's Disease With Psychotic Features. primary care companion for CNS disorders, <i>The</i> , 2021, 23, .	0.6	1

#	ARTICLE	IF	CITATIONS
91	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. NPJ Schizophrenia, 2021, 7, 41.	3.6	6
92	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. World Psychiatry, 2021, 20, 417-436.	10.4	127
93	Individuals at increased risk for development of bipolar disorder display structural alterations similar to people with manifest disease. Translational Psychiatry, 2021, 11, 485.	4.8	13
94	Withdrawal-associated relapse is a potential source of bias – Authors' reply. Lancet Psychiatry, the, 2021, 8, 748-749.	7.4	0
95	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. American Journal of Psychiatry, 2021, 178, 793-803.	7.2	50
96	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry, the, 2021, 8, 883-891.	7.4	50
97	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
98	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs, 2021, 35, 39-59.	5.9	67
99	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2021, 47, 986-996.	4.3	9
100	What are the physical and mental health implications of duration of untreated psychosis?. European Psychiatry, 2021, 64, e46.	0.2	3
101	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. Psychosomatic Medicine, 2021, 83, 85-93.	2.0	15
102	Appraising the effectiveness of electrical and magnetic brain stimulation techniques in acute major depressive episodes: an umbrella review of meta-analyses of randomized controlled trials. Revista Brasileira De Psiquiatria, 2021, 43, 514-524.	1.7	15
103	Symptoms and Characteristics of Youth Hospitalized for Depression: Subthreshold Manic Symptoms Can Help Differentiate Bipolar from Unipolar Depression. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 545-552.	1.3	5
104	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs, 2021, 35, 1189-1205.	5.9	32
105	Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. Journal of Clinical Psychiatry, 2021, 82, .	2.2	1
106	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, With First Episode Psychosis. Journal of Clinical Psychopharmacology, 2021, 41, 667-672.	1.4	2
107	Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA Psychiatry, 2021, , .	11.0	4
108	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophrenia, 2021, 7, 63.	3.6	39

#	ARTICLE	IF	CITATIONS
109	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 808002.	2.6	14
110	Reasons for admission and variance of body weight at referral in female inpatients with anorexia nervosa in Germany. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2021, 15, 78.	2.5	4
111	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e14.	3.9	20
112	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , 2020, 50, 1356-1367.	4.5	26
113	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 41-49.	1.9	13
114	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. <i>Schizophrenia Research</i> , 2020, 215, 408-415.	2.0	31
115	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	3.2	4
116	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 225.	11.0	14
117	Incontinence and constipation in adolescent patients with anorexia nervosa—Results of a multicenter study from a German web-based registry for children and adolescents with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2020, 53, 219-228.	4.0	14
118	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , 2020, 19, 61-68.	10.4	232
119	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020, 6, 1.	3.6	193
120	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. <i>Child and Adolescent Mental Health</i> , 2020, 25, 79-94.	3.5	0
121	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 349.	11.0	226
122	Metformin addition vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	10.4	68
123	Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 119-122.	1.3	15
124	Better care for less money: cost-effectiveness of integrated care in multi-episode patients with severe psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 221-230.	4.5	9
125	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 140-151.	1.7	0
126	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.0	23

#	ARTICLE	IF	CITATIONS
127	Most recommended medical interventions reach $P < 0.005$ for their primary outcomes in meta-analyses. <i>International Journal of Epidemiology</i> , 2020, 49, 885-893.	1.9	10
128	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4717839 people. <i>Lancet Psychiatry</i> , the, 2020, 7, 52-63.	7.4	109
129	What is good mental health? A scoping review. <i>European Neuropsychopharmacology</i> , 2020, 31, 33-46.	0.7	131
130	M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S214-S214.	4.3	3
131	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
132	Medical management of eating disorders: an update. <i>Current Opinion in Psychiatry</i> , 2020, 33, 542-553.	6.3	31
133	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , the, 2020, 7, 749-761.	7.4	66
134	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , the, 2020, 7, 813-824.	7.4	1,101
135	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52
136	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 568982.	2.6	7
137	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 141-145.	2.2	4
138	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 41, 28-39.	0.7	56
139	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094270.	2.7	21
140	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	7.2	72
141	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. <i>Drugs</i> , 2020, 80, 1763-1781.	10.9	39
142	Association between mental disorders and somatic conditions: protocol for an umbrella review. <i>Evidence-Based Mental Health</i> , 2020, 23, 135-139.	4.5	16
143	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	2.4	102
144	Adapting to the impact of COVID-19 on mental health: an international perspective. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 229-233.	2.4	8

#	ARTICLE	IF	CITATIONS
145	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, E1-E2.	2.4	1
146	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia – Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , 2020, 46, 1459-1470.	4.3	58
147	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 376-380.	1.3	16
148	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i> , 2020, 19, 214-232.	10.4	167
149	Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 491-495.	2.1	3
150	Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: Results from a prespecified interim analysis of a multicenter, randomized, controlled study. <i>Bipolar Disorders</i> , 2020, 22, 517-529.	1.9	14
151	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	11.0	287
152	Assessment of Physical Activity Patterns in Adolescent Patients with Anorexia Nervosa and Their Effect on Weight Gain. <i>Journal of Clinical Medicine</i> , 2020, 9, 727.	2.4	5
153	Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. <i>JAMA Psychiatry</i> , 2020, 77, 977.	11.0	53
154	Psychological and nutritional correlates of objectively assessed physical activity in patients with anorexia nervosa. <i>European Eating Disorders Review</i> , 2020, 28, 559-570.	4.1	6
155	The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. <i>BMC Psychiatry</i> , 2020, 20, 77.	2.6	14
156	<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 519-534.	2.2	339
157	Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 222-234.	1.3	8
158	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , 2020, 218, 195-200.	2.0	16
159	Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 366-375.	1.3	3
160	Cultural Influences in Psychiatry – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1193.	7.4	0
161	100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. <i>CNS Spectrums</i> , 2020, 25, 265-265.	1.2	1
162	104 Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents with Schizophrenia: Analysis of a Two-Year Study. <i>CNS Spectrums</i> , 2020, 25, 267-268.	1.2	0

#	ARTICLE	IF	CITATIONS
163	Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. <i>Schizophrenia Research</i> , 2020, 220, 123-129.	2.0	11
164	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 1547-1557.	4.3	17
165	Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. <i>Frontiers in Neurology</i> , 2020, 11, 610614.	2.4	5
166	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. <i>European Neuropsychopharmacology</i> , 2020, 35, 1-11.	0.7	12
167	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 456-465.	0.8	8
168	Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife). <i>International Journal of Bipolar Disorders</i> , 2020, 8, 22.	2.2	18
169	Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 14.	2.2	3
170	Outcomes of an Accelerated Inpatient Refeeding Protocol in 103 Extremely Underweight Adults with Anorexia Nervosa at a Specialized Clinic in Prien, Germany. <i>Journal of Clinical Medicine</i> , 2020, 9, 1535.	2.4	17
171	Antipsychotic Polypharmacy in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	16
172	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
173	Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	21
174	Current Treatment Options and Emerging Agents for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	15
175	Using Patient-Centered Assessment in Schizophrenia Care. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	16
176	Drs Kane and Correll Reply. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	0
177	Suicidality in Childhood and Adolescence. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 261-267.	0.9	24
178	Cariprazine in the management of negative symptoms of schizophrenia: state-of-the-art and future perspectives. <i>Future Neurology</i> , 2020, 15, .	0.5	7
179	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. <i>JAMA Psychiatry</i> , 2019, 76, 1052.	11.0	243
180	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 675-712.	7.4	815

#	ARTICLE	IF	CITATIONS
181	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 227-243.	4.5	59
182	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.7	38
183	Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa. <i>Nutrients</i> , 2019, 11, 2593.	4.1	27
184	Is Transcultural Psychiatry Possible?. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2167.	7.4	18
185	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , 2019, 19, 362.	2.6	35
186	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.9	71
187	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. <i>Schizophrenia Bulletin</i> , 2019, 45, S197-S197.	4.3	0
188	Mullerian inhibiting substance, sex hormone binding globulin and sex hormone levels in stimulant-naïve, first-diagnosed prepubertal boys with attention-deficit/hyperactivity disorder: comparison with matched healthy controls as well as before and after oros-methylphenidate treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 251-257.	2.4	4
189	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	1.2	87
190	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , 2019, 33, 1227-1236.	4.0	24
191	Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. <i>PLoS ONE</i> , 2019, 14, e0210674.	2.5	2
192	<p>Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2537-2550.	2.2	20
193	Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 350-362.	8.8	60
194	Association of Antidepressant Use With Adverse Health Outcomes. <i>JAMA Psychiatry</i> , 2019, 76, 1241.	11.0	143
195	Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it Tj ETQq1 1 0.784314 rgBT /Overlock	4.5	1
196	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. <i>Movement Disorders</i> , 2019, 34, 1203-1209.	3.9	18
197	<p></p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1365-1379.	2.2	28
198	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , 2019, 18, 208-224.	10.4	93

#	ARTICLE	IF	CITATIONS
199	Longitudinal outcomes in pediatric and adult onset bipolar patients compared to healthy and schizophrenia controls. <i>Bipolar Disorders</i> , 2019, 21, 514-524.	1.9	7
200	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerability and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1062-1078.	0.5	16
201	84 Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. <i>CNS Spectrums</i> , 2019, 24, 217-218.	1.2	0
202	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	1.9	8
203	Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. <i>Psychiatry Research</i> , 2019, 274, 176-181.	3.3	8
204	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial. <i>Psychiatry Research</i> , 2019, 273, 631-640.	3.3	11
205	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 499.	11.0	191
206	Bipolar Prodrome Symptom Scale - Abbreviated Screen for Patients: Description and validation. <i>Journal of Affective Disorders</i> , 2019, 249, 357-365.	4.1	17
207	Patches. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	24
208	Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	15
209	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	157
210	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019. <i>Current Psychiatry Reports</i> , 2019, 21, 124.	4.5	16
211	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
212	Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , 2019, 24, 479-495.	1.2	17
213	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	1.2	15
214	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , 2019, 24, 354-370.	1.2	17
215	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 26-36.	4.5	30
216	Creativity in persons at risk for bipolar disorder? A pilot study. <i>Microbial Biotechnology</i> , 2019, 13, 1165-1172.	1.7	10

#	ARTICLE	IF	CITATIONS
217	Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. <i>CNS Spectrums</i> , 2019, 24, 507-517.	1.2	12
218	Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. <i>CNS Spectrums</i> , 2019, 24, 313-321.	1.2	11
219	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years. <i>Schizophrenia Bulletin</i> , 2019, 45, 315-329.	4.3	141
220	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	35
221	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. <i>Meta Gene</i> , 2018, 16, 143-164.	0.6	1
222	The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. <i>Molecular Metabolism</i> , 2018, 12, 1-11.	6.5	19
223	O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT. <i>Schizophrenia Bulletin</i> , 2018, 44, S93-S94.	4.3	0
224	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 21-27.	0.6	89
225	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 187-205.	4.5	59
226	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 158-165.	1.3	43
227	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	3.1	80
228	Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 965-975.	4.7	20
229	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	11.0	516
230	S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S363-S363.	4.3	0
231	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 194, 4-12.	2.0	65
232	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	4.3	137
233	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	7.2	46
234	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	2.0	42

#	ARTICLE	IF	CITATIONS
235	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	3.1	7
236	Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. <i>Journal of Personality Disorders</i> , 2018, 32, 823-837.	1.4	22
237	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). <i>Schizophrenia Research</i> , 2018, 193, 377-383.	2.0	22
238	144 A Clinical Practice Assessment In Tardive Dyskinesia: Are Physicians Up-to-Date?. <i>CNS Spectrums</i> , 2018, 23, 89-90.	1.2	0
239	Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. <i>BMC Psychiatry</i> , 2018, 18, 365.	2.6	22
240	Mobility for All?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 792-793.	0.5	0
241	Whatâ€™s in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 719-721.	0.5	13
242	The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2018, 7, 289.	2.4	11
243	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <i>European Psychiatry</i> , 2018, 54, 124-144.	0.2	377
244	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , 2018, 69, 1259-1263.	2.0	31
245	Disturbing Lack of Early Intervention Studies in Bipolar Disorderâ€”Reply. <i>JAMA Psychiatry</i> , 2018, 75, 1202.	11.0	0
246	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	1.7	12
247	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 303-318.	2.7	129
248	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S86-S86.	4.3	5
249	Tardive dyskinesia risk with firstâ€•and secondâ€•generation antipsychotics in comparative randomized controlled trials: a metaâ€•analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	10.4	117
250	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1215-1238.	4.3	51
251	S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S341-S342.	4.3	0
252	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 570-576.	1.4	17

#	ARTICLE	IF	CITATIONS
253	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	10.4	188
254	S27. RELIABILITY OF SCHIZOPHRENIA DIAGNOSES IN CHILDREN AND ADOLESCENTS IN DENMARK. <i>Schizophrenia Bulletin</i> , 2018, 44, S333-S333.	4.3	0
255	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , 2018, 105, 23-32.	3.1	71
256	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1463-1474.	2.2	26
257	Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. <i>Evidence-Based Mental Health</i> , 2018, 21, e11-e11.	4.5	0
258	The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 537-542.	3.9	31
259	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1475-1492.	2.2	21
260	Systematic review and guide to management of core and psychiatric symptoms in youth with autism. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 379-400.	4.5	37
261	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. <i>Journal of Neural Transmission</i> , 2018, 125, 89-102.	2.8	21
262	Long-Acting Injectable Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2018, 79, AL17017WC1C.	2.2	3
263	Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16-23.	2.2	56
264	Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-Control Study. <i>Perspectives in Psychiatric Care</i> , 2017, 53, 67-72.	1.9	9
265	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 593-609.	2.8	65
266	Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. <i>Psychiatry Research</i> , 2017, 248, 134-139.	3.3	8
267	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. <i>Ageing Research Reviews</i> , 2017, 35, 63-73.	10.9	182
268	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
269	Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. <i>Evidence-Based Mental Health</i> , 2017, 20, e6-e6.	4.5	5
270	Pain perception in Parkinson's disease: A systematic review and meta-analysis of experimental studies. <i>Ageing Research Reviews</i> , 2017, 35, 74-86.	10.9	35

#	ARTICLE	IF	CITATIONS
271	Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. <i>CNS Spectrums</i> , 2017, 22, 415-426.	1.2	59
272	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , 2017, 253, 296-302.	3.3	13
273	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , 2017, 16, 163-180.	10.4	1,082
274	A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. <i>Schizophrenia Bulletin</i> , 2017, 43, 64-74.	4.3	54
275	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	11.0	153
276	Ï‰-3 Polyunsaturated Fatty Acids to Prevent Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 11.	11.0	12
277	Analgesic Effects of Alcohol: A Systematic Review and Meta-Analysis of Controlled Experimental Studies in Healthy Participants. <i>Journal of Pain</i> , 2017, 18, 499-510.	1.4	119
278	Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. <i>Psychiatry Research</i> , 2017, 255, 198-203.	3.3	9
279	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	11.0	135
280	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. <i>Lancet Psychiatry</i> , 2017, 4, 605-618.	7.4	40
281	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 1-14.	2.7	20
282	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , 2017, 185, 167-172.	2.0	29
283	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 1173.	11.0	5
284	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. <i>Bipolar Disorders</i> , 2017, 19, 524-543.	1.9	152
285	Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism and Eating Disorders: Data From a New Biobank and Meta-Analysis of Previously Published Studies. <i>European Eating Disorders Review</i> , 2017, 25, 524-532.	4.1	6
286	Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 634-635.	0.5	4
287	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 784-792.	0.5	21
288	A new class of VMAT-2 inhibitors for tardive dyskinesia. <i>Lancet Psychiatry</i> , 2017, 4, 574-575.	7.4	3

#	ARTICLE	IF	CITATIONS
289	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2017, 8, 292.	2.6	16
290	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 757-777.	2.0	286
291	Leptin and Physical Activity in Adult Patients with Anorexia Nervosa: Failure to Demonstrate a Simple Linear Association. <i>Nutrients</i> , 2017, 9, 1210.	4.1	14
292	Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e933-e939.	2.2	38
293	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1035-e1046.	2.2	36
294	Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e744-e781.	2.2	21
295	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	2.2	6
296	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e264-e278.	2.2	179
297	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e957-e969.	2.2	45
298	The Effects of Valbenazine in Participants with Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1344-1350.	2.2	67
299	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1136-1147.	2.2	58
300	Epidemiology and Prevention of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1426.	2.2	8
301	Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 347-357.	2.2	4
302	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 53-60.	0.0	16
303	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 69-76.	0.0	14
304	Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 68-72.	0.1	12
305	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. <i>Addiction</i> , 2016, 111, 1914-1922.	3.3	65
306	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. <i>CNS Drugs</i> , 2016, 30, 997-1006.	5.9	12

#	ARTICLE	IF	CITATIONS
307	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	2.7	31
308	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. <i>Psychological Medicine</i> , 2016, 46, 623-635.	4.5	108
309	Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 341-351.	4.5	94
310	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	1.3	88
311	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 93-98.	2.0	49
312	Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 71-76.	2.0	47
313	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	4.3	149
314	Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 9-17.	3.9	19
315	Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. <i>Psychological Medicine</i> , 2016, 46, 1069-1078.	4.5	23
316	The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 543-555.	0.5	129
317	Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. <i>Schizophrenia Research</i> , 2016, 174, 82-92.	2.0	44
318	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 601-614.	2.8	40
319	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 456-468.e4.	0.5	57
320	Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. <i>Psychological Medicine</i> , 2016, 46, 1459-1472.	4.5	292
321	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 410-427.	1.3	104
322	Premature Mortality and Schizophrenia—The Need to Heal Right From the Start. <i>JAMA Psychiatry</i> , 2016, 73, 535.	11.0	7
323	Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 385-398.	4.5	51
324	Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. <i>Journal of Pain</i> , 2016, 17, 1257-1272.	1.4	114

#	ARTICLE	IF	CITATIONS
325	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. <i>Schizophrenia Research</i> , 2016, 176, 220-230.	2.0	97
326	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , 2016, 15, 166-174.	10.4	487
327	Prevalence of aggression in hospitalized patients with schizophrenia in China: A meta-analysis. <i>Asia-Pacific Psychiatry</i> , 2016, 8, 60-69.	2.2	58
328	Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 221-223.	3.8	1
329	Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. <i>CNS Spectrums</i> , 2016, 21, 466-477.	1.2	14
330	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , 2016, 14, 189.	5.5	119
331	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. <i>Psychiatric Services</i> , 2016, 67, 1035-1038.	2.0	23
332	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , 2016, 81, 95-101.	3.1	70
333	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. <i>CNS Spectrums</i> , 2016, 21, 393-402.	1.2	28
334	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	1.3	20
335	Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders. <i>Internet Interventions</i> , 2016, 4, 35-42.	2.7	24
336	Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>Perspectives in Psychiatric Care</i> , 2016, 52, 4-11.	1.9	16
337	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. <i>JAMA Psychiatry</i> , 2016, 73, 247.	11.0	189
338	Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. <i>Journal of Affective Disorders</i> , 2016, 197, 268-280.	4.1	16
339	Smoking in male patients with schizophrenia in China: A meta-analysis. <i>Drug and Alcohol Dependence</i> , 2016, 162, 146-153.	3.2	36
340	Worldwide Differences in Regulations of Clozapine Use. <i>CNS Drugs</i> , 2016, 30, 149-161.	5.9	139
341	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 187.	11.0	72
342	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 921-936.	1.8	26

#	ARTICLE	IF	CITATIONS
343	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 591-612.	2.4	29
344	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1091-1102.	4.7	26
345	Poor Sleep Is Related to Lower Emotional Competence Among Adolescents. <i>Behavioral Sleep Medicine</i> , 2016, 14, 602-614.	2.1	68
346	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , 2016, 173, 362-372.	7.2	601
347	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1-24.	2.2	267
348	Low Hemoglobin Levels and Risk of Developing Depression in the Elderly. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1549-e1556.	2.2	22
349	Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e746-e756.	2.2	33
350	Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. <i>Shanghai Archives of Psychiatry</i> , 2016, 28, 241-252.	0.7	4
351	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , 2015, 14, 56-63.	10.4	82
352	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. <i>World Psychiatry</i> , 2015, 14, 119-136.	10.4	581
353	Schizophrenia. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15067.	30.5	724
354	The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. <i>Psychological Medicine</i> , 2015, 45, 3341-3354.	4.5	35
355	Decreased pain sensitivity among people with schizophrenia. <i>Pain</i> , 2015, 156, 2121-2131.	4.2	95
356	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 97-108.	4.5	216
357	Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1665-1675.	3.8	43
358	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. <i>BMC Psychiatry</i> , 2015, 15, 271.	2.6	13
359	Delayed identification and diagnosis of Huntington's disease due to psychiatric symptoms. <i>International Journal of Mental Health Systems</i> , 2015, 9, 33.	2.7	9
360	Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. <i>Obesity Reviews</i> , 2015, 16, 1001-1015.	6.5	138

#	ARTICLE	IF	CITATIONS
361	Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2015, 30, 272-281.	1.7	25
362	Perfectionism related to self-reported insomnia severity, but not when controlled for stress and emotion regulation. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 263.	2.2	45
363	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 280-288.	1.7	19
364	Use of electroconvulsive therapy for Asian patients with schizophrenia (2001â€“2009): Trends and correlates. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 489-496.	1.8	30
365	Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. <i>American Journal of Psychiatry</i> , 2015, 172, 986-994.	7.2	128
366	Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, doseâ€“response study. <i>Psychoneuroendocrinology</i> , 2015, 58, 130-140.	2.7	52
367	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
368	Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and metaâ€“analysis. <i>World Psychiatry</i> , 2015, 14, 339-347.	10.4	858
369	Temperament and prodromal symptoms prior to first manic/hypomanic episodes: Results from a pilot study. <i>Journal of Affective Disorders</i> , 2015, 173, 39-44.	4.1	21
370	A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. <i>Psychological Medicine</i> , 2015, 45, 299-317.	4.5	105
371	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.5	32
372	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.7	56
373	Importando la Escala de SÃntomas ProdrÃ3micos Bipolares-Prospectiva Completa.. <i>Psiquiatria Biologica</i> , 2015, 22, 30-31.	0.1	0
374	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1669-1676.	0.7	27
375	Glutamatergic agents for schizophrenia: current evidence and perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 335-352.	3.1	29
376	Antipsychotic Use in Youth Without Psychosis. <i>JAMA Psychiatry</i> , 2015, 72, 859.	11.0	32
377	Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1181-1199.	2.4	19
378	A functional polymorphism in the interleukin-1beta and severity of nicotine dependence in male schizophrenia: A case-control study. <i>Journal of Psychiatric Research</i> , 2015, 64, 51-58.	3.1	6

#	ARTICLE	IF	CITATIONS
379	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2015, 172, 870-880.	7.2	158
380	Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 797-814.	4.7	20
381	Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 351-361.	1.3	35
382	Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 129-136.	2.3	40
383	Ambiguous findings concerning potential advantages of depot antipsychotics. <i>Current Opinion in Psychiatry</i> , 2015, 28, 216-221.	6.3	47
384	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , 2015, 66, 753-756.	2.0	100
385	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	1.3	8
386	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1485-1496.	4.7	18
387	Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1587-1608.	2.4	19
388	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	4.3	100
389	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). <i>Schizophrenia Research</i> , 2015, 168, 523-529.	2.0	17
390	Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. <i>General Hospital Psychiatry</i> , 2015, 37, 621.e3-621.e4.	2.4	2
391	Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 219-241.	2.4	29
392	Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 25-36.	0.5	62
393	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	7.2	80
394	Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients?. <i>Journal of Affective Disorders</i> , 2015, 172, 191-194.	4.1	9
395	Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. <i>Psychoneuroendocrinology</i> , 2015, 51, 237-252.	2.7	164
396	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 627-636.	4.3	44

#	ARTICLE	IF	CITATIONS
397	Frequency and Correlates of DSM-5 Attenuated Psychosis Syndrome in a Sample of Adolescent Inpatients With Nonpsychotic Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1449-e1458.	2.2	20
398	Frequency and Correlates of Distant Visual Impairment in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>East Asian Archives of Psychiatry</i> , 2015, 25, 115-21.	0.4	5
399	Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 901.	2.0	11
400	Child and Adolescent Psychiatrists' Attitudes and Practices Prescribing Second Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 90-93.	1.3	26
401	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 229-241.	2.6	18
402	Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. <i>Pediatrics</i> , 2014, 134, e1308-e1314.	2.1	36
403	The Bipolar Prodrome Symptom Interview and Scaleâ€“Prospective (<scp>BPSS</scp>â€“): description and validation in a psychiatric sample and healthy controls. <i>Bipolar Disorders</i> , 2014, 16, 505-522.	1.9	77
404	Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China. <i>Perspectives in Psychiatric Care</i> , 2014, 50, 257-263.	1.9	10
405	Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: a systematic review. <i>Microbial Biotechnology</i> , 2014, 8, 3-11.	1.7	29
406	Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001â€“2009). <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 359-366.	2.7	19
407	The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis. <i>Schizophrenia Research</i> , 2014, 160, 1-8.	2.0	70
408	National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians. <i>JAMA Psychiatry</i> , 2014, 71, 81.	11.0	368
409	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	2.6	10
410	Critical Issues on the Use of Network Meta-analysis in Psychiatry. <i>Harvard Review of Psychiatry</i> , 2014, 22, 367-372.	2.1	19
411	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	11.0	318
412	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 35-53.	1.2	132
413	Efficacy of Pharmacologic and Psychotherapeutic Interventions in Psychiatry. <i>JAMA Psychiatry</i> , 2014, 71, 624.	11.0	6
414	Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: Baseline results in the first 180 help-seeking individuals assessed at the dresden high-risk project. <i>Journal of Affective Disorders</i> , 2014, 152-154, 427-433.	4.1	23

#	ARTICLE	IF	CITATIONS
415	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	4.3	332
416	Prevalence of Nurses' Smoking Habits in Psychiatric and General Hospitals in China. <i>Archives of Psychiatric Nursing</i> , 2014, 28, 119-122.	1.4	12
417	Antidepressants for cognitive impairment in schizophrenia – A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	2.0	48
418	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.5	76
419	Markers of inflammation in schizophrenia: association vs. causation. <i>World Psychiatry</i> , 2014, 13, 189-192.	10.4	54
420	Emerging drugs for schizophrenia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 511-531.	2.4	44
421	Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. <i>Bipolar Disorders</i> , 2014, 16, 451-454.	1.9	7
422	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , 2014, 3, 187.	1.2	10
423	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.0	20
424	Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 161.	1.6	25
425	Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 971-979.e6.	0.5	22
426	Efficacy and Safety of Atomoxetine in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Results From a Comprehensive Meta-Analysis and Metaregression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 174-187.	0.5	131
427	Alpha-2 Agonists for Attention-Deficit/Hyperactivity Disorder in Youth: A Systematic Review and Meta-Analysis of Monotherapy and Add-On Trials to Stimulant Therapy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 153-173.	0.5	132
428	Frequency of Involuntary Admissions and Its Associations With Demographic and Clinical Characteristics in China. <i>Archives of Psychiatric Nursing</i> , 2014, 28, 272-276.	1.4	26
429	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , 2014, 155, 72-76.	2.0	68
430	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , 2014, 16, 478-492.	1.9	91
431	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.1	48
432	Symptomatic and functional remission of subjects at clinical high risk for psychosis: A 2-year naturalistic observational study. <i>Schizophrenia Research</i> , 2014, 156, 266-271.	2.0	46

#	ARTICLE	IF	CITATIONS
433	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1095-1105.	2.1	45
434	Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics. <i>JAMA Psychiatry</i> , 2014, 71, 209.	11.0	17
435	Prioritization of Research Addressing Antipsychotics for Adolescents and Young Adults With Bipolar Disorder. <i>Annals of Internal Medicine</i> , 2014, 160, 492.	3.9	3
436	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. <i>BMJ Open</i> , 2014, 4, e005708.	1.9	8
437	Prospective Memory Performance in Non-Psychotic First-Degree Relatives of Patients with Schizophrenia: A Controlled Study. <i>PLoS ONE</i> , 2014, 9, e111562.	2.5	14
438	Clinical predictors of therapeutic response to antipsychotics in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 505-524.	3.7	186
439	Recognition of Patients Who Would Benefit From LAI Antipsychotic Treatment. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e29-e29.	2.2	10
440	The Role of the Extended Health Care Team in Successful LAI Therapy. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e25.	2.2	4
441	Schizophrenia: Mechanism of Action of Current and Novel Treatments. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 347-348.	2.2	14
442	National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 490-497.	2.2	34
443	Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e573-e577.	2.2	37
444	Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. <i>East Asian Archives of Psychiatry</i> , 2014, 24, 37-8.	0.4	24
445	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 795-807.	2.8	11
446	Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 2013, 23, 205-211.	0.7	10
447	Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. <i>Current Psychiatry Reports</i> , 2013, 15, 382.	4.5	35
448	Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. <i>World Psychiatry</i> , 2013, 12, 155-164.	10.4	249
449	Rational Use of Generic Psychotropic Drugs. <i>CNS Drugs</i> , 2013, 27, 353-365.	5.9	21
450	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 31.	2.5	19

#	ARTICLE	IF	CITATIONS
451	Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. <i>Bipolar Disorders</i> , 2013, 15, 507-523.	1.9	129
452	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , 2013, 209, 406-411.	3.3	28
453	The bipolar disorder prodrome revisited: Is there a symptomatic pattern?. <i>Journal of Affective Disorders</i> , 2013, 151, 551-560.	4.1	34
454	Antipsychotics for acute schizophrenia: making choices. <i>Lancet</i> , The, 2013, 382, 919-920.	13.7	14
455	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.5	23
456	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.9	62
457	Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. <i>Schizophrenia Research</i> , 2013, 143, 358-362.	2.0	21
458	Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 522-530.	1.3	35
459	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013, 18, 53-66.	7.9	136
460	Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2013, 39, 1230-1241.	4.3	168
461	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1205-1218.	2.1	257
462	Prediction of Functional Outcome in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 1133.	11.0	202
463	Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. <i>Journal of ECT</i> , 2013, 29, 271-276.	0.6	17
464	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 186-192.	1.4	30
465	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	6.3	82
466	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <i>World Psychiatry</i> , 2013, 12, 240-250.	10.4	220
467	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	10.4	356
468	Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators. <i>American Journal of Psychiatry</i> , 2013, 170, 265-274.	7.2	336

#	ARTICLE	IF	CITATIONS
469	Prescribing of psychotropic medications to children and adolescents: <i>quo vadis</i>?. World Psychiatry, 2013, 12, 127-128.	10.4	9
470	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 665-675.	1.3	30
471	Frequency, Characteristics and Management of Adolescent Inpatient Aggression. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 271-281.	1.3	45
472	The Significance of At-Risk or Prodromal Symptoms for Bipolar I Disorder in Children and Adolescents. Canadian Journal of Psychiatry, 2013, 58, 22-31.	1.9	51
473	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, 957-965.	2.2	371
474	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. Trends in Psychiatry and Psychotherapy, 2013, 35, 62-75.	0.8	1
475	Pediatric Schizophrenia. , 2013, , 1-6.		0
476	The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Danish Medical Journal, 2013, 60, A4578.	0.5	118
477	National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics. Archives of General Psychiatry, 2012, 69, 1247.	12.3	312
478	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. Schizophrenia Bulletin, 2012, 38, 1-4.	4.3	6
479	Osteoporosis and fracture risk in people with schizophrenia. Current Opinion in Psychiatry, 2012, 25, 415-429.	6.3	91
480	Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 678-683.	1.4	75
481	Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2012, 32, 458-464.	1.4	14
482	Differences in Body Mass Index <i>z</i>-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 166-173.	1.3	18
483	Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine, 2012, 42, 125-147.	4.5	278
484	Ask the Expert: Schizophrenia. Focus (American Psychiatric Publishing), 2012, 10, 154-156.	0.8	0
485	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology, 2012, 8, 114-126.	9.6	832
486	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. Archives of General Psychiatry, 2012, 69, 904.	12.3	165

#	ARTICLE	IF	CITATIONS
487	Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. <i>CNS Drugs</i> , 2012, 26, 733-759.	5.9	136
488	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 527-542.	2.4	163
489	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , 2012, 140, 159-168.	2.0	161
490	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. <i>Schizophrenia Research</i> , 2012, 138, 18-28.	2.0	255
491	Antipsychotic Polypharmacy. <i>Psychiatric Clinics of North America</i> , 2012, 35, 661-681.	1.3	93
492	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012, 3, 62.	2.6	25
493	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. <i>Pediatrics</i> , 2012, 129, e1577-e1586.	2.1	117
494	Risk constellations prior to the development of bipolar disorders: Rationale of a new risk assessment tool. <i>Journal of Affective Disorders</i> , 2012, 136, 1000-1010.	4.1	90
495	Antipsychotic Drug Administration Does Not Correlate with Prolonged Rate-Corrected QT Interval in Children and Adolescents: Results from a Nested Case-Control Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 365-368.	1.3	28
496	Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. <i>European Psychiatry</i> , 2011, 26, 3-16.	0.2	19
497	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 517-535.	1.3	221
498	Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. <i>Schizophrenia Research</i> , 2011, 131, 58-62.	2.0	78
499	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631
500	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , 2011, 17, 97-107.	6.7	256
501	Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. <i>British Journal of Psychiatry</i> , 2011, 199, 99-105.	2.8	169
502	Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. <i>European Psychiatry</i> , 2011, 26, 144-158.	0.2	302
503	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.7	168
504	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1738-1746.	5.4	45

#	ARTICLE	IF	CITATIONS
505	Quantifying Clinical Relevance in the Treatment of Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, B16-B39.	2.5	94
506	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 417-423.	3.2	29
507	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2245-2263.	1.8	0
508	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. <i>Postgraduate Medicine</i> , 2011, 123, 135-159.	2.0	11
509	Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2011, 168, 806-813.	7.2	164
510	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
511	Experts' Recommendations for Treating Maladaptive Aggression in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 505-515.	1.3	23
512	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 155-172.	3.7	38
513	What Are We Looking for in New Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 9-13.	2.2	16
514	QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 854-860.	2.2	24
515	Sudden Deaths in Psychiatric Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 936-941.	2.2	60
516	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1616-1627.	2.2	43
517	Developments in Pediatric Psychopharmacology. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 655-670.	2.2	109
518	Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients. <i>Psychiatric Services</i> , 2010, 61, 892-898.	2.0	87
519	Switching and Combining Antipsychotics. <i>CNS Spectrums</i> , 2010, 15, 8-11.	1.2	7
520	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 390-431.	5.2	167
521	10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 356-366.	4.5	69
522	Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 341-344.	4.5	20

#	ARTICLE	IF	CITATIONS
523	Evidence-based flying taking off: maximising the effectiveness of a novel airline user decision-making tool. <i>International Journal of Clinical Practice</i> , 2010, 64, 1836-1837.	1.7	1
524	<i>Primum non nocere</i> balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 113-115.	1.9	14
525	Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , 2010, 12, 116-141.	1.9	181
526	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	2.2	188
527	Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. <i>Evidence-Based Mental Health</i> , 2010, 13, 54-54.	4.5	1
528	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	5.4	183
529	Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. <i>Schizophrenia Research</i> , 2010, 123, 59-63.	2.0	56
530	From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. <i>European Psychiatry</i> , 2010, 25, S12-S21.	0.2	215
531	Management of physical health in patients with schizophrenia: practical recommendations. <i>European Psychiatry</i> , 2010, 25, S41-S45.	0.2	34
532	Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2010, 35, 1520-1530.	5.4	206
533	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , 2010, 117, 68-74.	2.0	99
534	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1175-1200.	2.8	95
535	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	3.7	86
536	Understanding Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 8-13.	2.2	10
537	Symptomatic Presentation and Initial Treatment for Schizophrenia in Children and Adolescents. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e29.	2.2	4
538	Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or Oppositionality. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 563-573.	1.3	50
539	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2009, 35, 443-457.	4.3	360
540	AACAP 2006 Research Forum "Advancing Research in Early-Onset Bipolar Disorder: Barriers and Suggestions. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 3-12.	1.3	21

#	ARTICLE	IF	CITATIONS
541	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1765.	7.4	867
542	The QTc interval and its dispersion in patients receiving two atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 23-27.	3.2	21
543	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , 2009, 19, 629-635.	0.7	184
544	Frequency and Correlates of Inappropriate Pediatric Psychiatric Emergency Room Visits. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1164-1177.	2.2	52
545	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1348-1357.	2.2	105
546	Diagnosis and treatment in the early illness phase of bipolar disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 50-54.	3.2	32
547	Cost of antipsychotic polypharmacy in the treatment of schizophrenia. <i>BMC Psychiatry</i> , 2008, 8, 19.	2.6	54
548	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. <i>Bipolar Disorders</i> , 2008, 10, 788-797.	1.9	143
549	Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. <i>International Review of Psychiatry</i> , 2008, 20, 195-201.	2.8	78
550	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 475-490.	1.3	50
551	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 9-20.	0.5	274
552	Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists. <i>Australasian Psychiatry</i> , 2008, 16, 253-262.	0.7	39
553	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 368-378.	0.8	6
554	Tardive dyskinesia and new antipsychotics. <i>Current Opinion in Psychiatry</i> , 2008, 21, 151-156.	6.3	331
555	Identification of High-Risk Coronary Heart Disease Patients Receiving Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 578-583.	2.2	6
556	Antipsychotic Polypharmacy, Part 1: Shotgun Approach or Targeted Cotreatment?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 674-675.	2.2	19
557	Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 860-861.	2.2	13
558	Elevated Cardiovascular Risk in Patients With Bipolar Disorder: When Does It Start and Where Does It Lead?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1948-1952.	2.2	16

#	ARTICLE	IF	CITATIONS
559	Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 26-36.	2.2	45
560	Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. <i>Schizophrenia Bulletin</i> , 2007, 33, 703-714.	4.3	175
561	One-Year Incidence Rates of Tardive Dyskinesia in Children and Adolescents Treated with Second-Generation Antipsychotics: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 647-655.	1.3	87
562	Acute and Long-Term Adverse Effects of Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 10-14.	1.2	29
563	Balancing Efficacy and Safety in Treatment with Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 12-20.	1.2	64
564	Pharmacological Management of Bipolar Disorder in a Youth With Diabetes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 1375-1379.	0.5	3
565	Weight Gain and Metabolic Effects of Mood Stabilizers and Antipsychotics in Pediatric Bipolar Disorder: A Systematic Review and Pooled Analysis of Short-Term Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 687-700.	0.5	143
566	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , 2007, 89, 91-100.	2.0	219
567	Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. <i>Schizophrenia Research</i> , 2007, 92, 103-107.	2.0	17
568	First-Episode Psychosis: A Window of Opportunity for Best Practices. <i>CNS Spectrums</i> , 2007, 12, 1-16.	1.2	18
569	Early identification and high-risk strategies for bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 324-338.	1.9	108
570	Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 546-557.	2.2	185
571	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 177-206.	1.9	163
572	Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 771-791.	0.5	343
573	Real-Life Switching Strategies With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 160-161.	2.2	31
574	Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 575-583.	2.2	175
575	Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. <i>BMC Psychiatry</i> , 2005, 5, 26.	2.6	148
576	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 418-433.	1.3	35

#	ARTICLE	IF	CITATIONS
577	Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2005, 162, 1217-1221.	7.2	89
578	Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story?. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1331-1332.	2.2	21
579	Real-Life Dosing With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1610-1611.	2.2	10
580	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	7.2	653
581	A Prospective Study of Hyperprolactinemia in Children and Adolescents Treated with Atypical Antipsychotic Agents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 350-358.	1.3	60
582	Pharmacogenetics of antipsychotic-induced weight gain. <i>Psychopharmacology</i> , 2004, 174, 477-89.	3.1	83
583	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 37-48.	2.0	207
584	Early Prediction of Antipsychotic Response in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 2063-2065.	7.2	159
585	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. <i>Schizophrenia Bulletin</i> , 2003, 29, 633-651.	4.3	327
586	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. <i>Schizophrenia Bulletin</i> , 2003, 29, 717-728.	4.3	67
587	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. <i>American Journal of Psychiatry</i> , 2003, 160, 1209-1222.	7.2	455
588	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. <i>Schizophrenia Bulletin</i> , 2003, 29, 747-756.	4.3	17
589	Unleashing the power of pooled and subgroup analyses in psychiatry. <i>International Clinical Psychopharmacology</i> , 0, Publish Ahead of Print, .	1.7	0